We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 11,988.00
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 4.00 (0.033%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 11,988.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-German COVID-19 cases are growing exponentially again -RKI

Tue, 16th Mar 2021 06:36

(Adds vaccination summit postponed, updates data)

BERLIN, March 16 (Reuters) - Coronavirus infections are
rising exponentially in Germany, an expert at the Robert Koch
Institute for infectious diseases said on Tuesday, adding that
the risk of AstraZeneca's vaccine was relatively low.

The number of cases per 100,000 reported on Tuesday was
83.7, up from 68 a week ago, and the RKI has said that metric
could reach 200 by the middle of next month.

"We are exactly on the flank of the third wave(of the
COVID-19 pandemic). That can no longer be disputed. And at this
point we have eased the restrictions and that is speeding up the
exponential growth," Dirk Brockmann, an epidemiologist at the
RKI, told Germany's ARD television.

Chancellor Angela Merkel and state leaders agreed a phased
easing of curbs earlier this month along with an "emergency
brake" to let authorities reimpose restrictions if case numbers
rise above 100 per 100,000 on three consecutive days.

On Tuesday, the number of cases per 100,000 rose to 83.7, up
from 68 a week ago, and the RKI has said that metric could reach
200 by the middle of next month.

On Monday, Germany suspended use of AstraZeneca's
COVID-19 vaccine, making it the latest of several European
countries to hit "pause" following reports of blood coagulation
disorders in recipients.

The decision followed a recommendation from the Paul Ehrlich
Institute (PEI), Germany's authority in charge of vaccines,
following seven cases of thrombosis, including three deaths.

A planned meeting between Merkel and state leaders on
Wednesday to discuss using family doctors to administer COVID-19
vaccines has been postponed until after the European Medicines
Agency completes its review into the AstraZeneca shot, a
government spokesman said.

AstraZeneca has said an analysis of its safety data covering
reported cases from over 17 million vaccine doses given had
shown no evidence of an increased risk of pulmonary embolism,
deep vein thrombosis or thrombocytopenia - having low levels of
platelets.

Brockmann said it made sense to explain the relative risks
to the population, noting that 1,000 people in a million had
died of COVID-19, compared to possibly 1 in a million from
complications associated with the vaccine.

"In the risk groups, the risk of dying of COVID is much,
much higher. That means it is probably 100,000 times more likely
to die of COVID than because of an AstraZeneca vaccine," he
said.
(Reporting by Emma Thomasson and Caroline Copley, Editing by
Riham Alkousaa, Shri Navaratnam and Timothy Heritage)

More News
Today 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
Today 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more
25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln

*

Read more
25 Apr 2024 09:18

TOP NEWS: AstraZeneca upbeat as cancer drugs underpin sales growth

(Alliance News) - AstraZeneca PLC on Thursday hailed the potential of its drugs pipeline as it delivered impressive growth in sales and profit in the first quarter.

Read more
25 Apr 2024 09:12

LONDON MARKET OPEN: Anglo American jumps on takeover bid from BHP

(Alliance News) - Stock prices in London opened mixed on Thursday, as investors cautiously eye data on the health of the US economy.

Read more
25 Apr 2024 08:38

AstraZeneca blows past analysts' estimates for Q1

(Sharecast News) - AstraZeneca posted better-than-expected revenues and profit for the first quarter of 2024 with both the company and analysts highlighting its drug pipeline.

Read more
25 Apr 2024 07:56

REPEAT: Miner Anglo American reviews takeover bid from rival BHP

(Alliance News) - Stocks in London are called to open slightly higher, after a busy start to the day, with corporate earnings and updates.

Read more
25 Apr 2024 07:52

Sanofi profit slips on generic competition and currency effects

April 25 (Reuters) - Sanofi's first-quarter operating income fell 14.7% as currency effects and cheap competition to its multiple sclerosis drug Aubagio outweighed rising sales of anti-inflammatory drug Dupixent, the French drugmaker said on Thursday.

Read more
25 Apr 2024 07:43

LONDON BRIEFING: Miner Anglo American eyes rival BHP takeover

(Alliance News) - Stocks in London are called to open slightly higher, after a busy start to the day, with corporate earnings and updates.

Read more
25 Apr 2024 06:30

Sanofi Q1 profit slips on generic competition, forex effects

April 25 (Reuters) - Sanofi's said on Thursday first-quarter operating income declined 14.7% as unfavourable currency effects and cheap competition to multiple sclerosis drug Aubagio outweighed rising sales of anti-inflammatory drug Dupixent.

Read more
24 Apr 2024 10:32

Angle shares jump on supplier agreement with with AstraZeneca

(Alliance News) - Angle PLC shares rose on Wednesday, after it signed a contract with AstraZeneca PLC.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.